Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, ...
Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300. ...
Posted by Michael Wonder on 16 Nov 2018
ICER issues final report on long-term prophylaxis for hereditary angioedema, provides policy recommendations to improve cost-effectiveness
15 November 2018 - Cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. ...
Posted by Michael Wonder on 14 Nov 2018
ICER report finds biologic treatments for uncontrolled asthma would require more than a 50% price discount to reach common thresholds for cost-effectiveness
13 November 2018 - Midwest CEPAC to vote on the overall value of treatments during 29 November public meeting. ...
Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038. ...
Posted by Michael Wonder on 24 Oct 2018
Institute for Clinical and Economic Review ends assessment of canakinumab for atherosclerosis
24 October 2018 - The Institute for Clinical and Economic Review today announced that it will not proceed with its comparative ...
Posted by Michael Wonder on 11 Oct 2018
ICER finds treatments prevent hereditary angioedema attacks, but cost-effectiveness uncertain and sensitive to frequency of attacks
11 October 2018 - As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient ...
Posted by Michael Wonder on 04 Oct 2018
ICER final report highlights uncertainty in long-term safety and effectiveness of new treatments for hereditary transthyretin amyloidosis, discusses options for insurance coverage criteria
4 October 2018 - The ICER today released a final evidence report and report-at-a-glance on inotersen (Akcea Therapeutics) and patisiran ...
Posted by Michael Wonder on 07 Sep 2018
ICER releases draft evidence report on medications for treatment of opioid use disorder
7 September 2018 - Public comment period now open until 4 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 30 Aug 2018
ICER finds current list price of patisiran for amyloidosis far exceeds standard cost-effectiveness levels
29 August 2018 - Report also evaluates evidence on inotersen; during public meeting of Midwest CEPAC on 13 September, a policy ...
Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...
Posted by Michael Wonder on 23 Aug 2018
ICER releases draft evidence report on long-term treatments for prevention of hereditary angioedema attacks
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 04 Aug 2018
ICER final report highlights limitations in evidence on long-term safety and effectiveness of elagolix for endometriosis, discusses options for insurance coverage criteria
3 August 2018 - Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first ...
Posted by Michael Wonder on 04 Aug 2018
ICER updated report on targeted treatments for plaque psoriasis finds guselkumab and risankizumab offer superior health benefit compared with TNFα inhibitors
3 August 2018 - Policy recommendations repeat call for insurers to minimise step therapy requirements on these treatments that are priced ...
Posted by Michael Wonder on 03 Jul 2018
ICER's final report on CGRP inhibitors for migraine prevention explores specific coverage policy options in light of responsible manufacturer pricing
3 July 2018 - Report notes the significant remaining uncertainty about the long-term safety of CGRP inhibitors given their new mechanism ...